campesterol has been researched along with Liver Steatosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kanno, K; Kishikawa, N; Mizooka, M; Sugiyama, A; Tazuma, S; Yokobayashi, K | 1 |
| Athias, A; Beacco, M; Bouillet, B; Brindisi, MC; Cercueil, JP; Duvillard, L; Guiu, B; Hillon, P; Petit, JM; Rollot, F; Verges, B | 1 |
2 other study(ies) available for campesterol and Liver Steatosis
| Article | Year |
|---|---|
Long-term administration of a Niemann-Pick C1-like 1 inhibitor, ezetimibe, does not worsen bile lithogenicity in dyslipidemic patients with hepatobiliary diseases.
Topics: Anticholesteremic Agents; Bile; Cholesterol; Dyslipidemias; Ezetimibe; Fatty Liver; Female; Gallstones; Humans; Lipid Metabolism; Lipoproteins; Male; Middle Aged; Phytosterols; Ursodeoxycholic Acid | 2016 |
Liver fat content is associated with an increase in cholesterol synthesis independent of statin therapy use in patients with type 2 diabetes.
Topics: Aged; Biomarkers; Cholesterol; Diabetes Mellitus, Type 2; Dyslipidemias; Fatty Liver; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Liver; Magnetic Resonance Spectroscopy; Male; Middle Aged; Multivariate Analysis; Non-alcoholic Fatty Liver Disease; Phytosterols; Risk Factors; Sitosterols; Treatment Outcome | 2012 |